Literature DB >> 10391409

Lower respiratory tract infection and pneumonia in the community.

J Macfarlane1.   

Abstract

Community-acquired pneumonia (CAP) is common. There is no entirely satisfactory way of defining pneumonia using clinical criteria alone. New focal chest signs on examination in the presence of a systemic illness that is suggestive of a lower respiratory tract infection seems to be the best clinical finding that indicates pneumonia. Progress has been made in identifying simple clinical features that relate to prognosis and allow the general practitioner to decide whether care in the community is appropriate or hospital referral is required. Psychosocial factors for the patient will also remain important. Most patients who have CAP that is mild enough to be managed in the community will require few, if any, investigations. A chest radiograph is appropriate in all patients to exclude an underlying lung tumor. Measurement of surrogate markers of acute infection, such as C-reactive protein, may prove useful to the general practitioner if near testing were to become feasible. The antibiotic management for CAP for patients well enough to be managed at home can be simple and logical, providing general practitioners have some knowledge regarding likely pathogens and etiologic and epidemiological clues. Any antibiotic chosen must suppress Streptococcus pneumoniae, which remains the most common cause of CAP.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10391409

Source DB:  PubMed          Journal:  Semin Respir Infect        ISSN: 0882-0546


  11 in total

1.  Do hospital physicians have a role in reducing antibiotic prescribing in the community?

Authors:  J Macfarlane; W F Holmes; R Macfarlane
Journal:  Thorax       Date:  2000-02       Impact factor: 9.139

2.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

Review 3.  Towards a sensible comprehension of severe community-acquired pneumonia.

Authors:  Santiago Ewig; Mark Woodhead; Antoni Torres
Journal:  Intensive Care Med       Date:  2010-11-16       Impact factor: 17.440

Review 4.  South African guideline for the management of community-acquired pneumonia in adults.

Authors:  Tom H Boyles; Adrian Brink; Greg L Calligaro; Cheryl Cohen; Keertan Dheda; Gary Maartens; Guy A Richards; Richard van Zyl Smit; Clifford Smith; Sean Wasserman; Andrew C Whitelaw; Charles Feldman
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

5.  Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community.

Authors:  J Macfarlane; W Holmes; P Gard; R Macfarlane; D Rose; V Weston; M Leinonen; P Saikku; S Myint
Journal:  Thorax       Date:  2001-02       Impact factor: 9.139

6.  Symptoms, signs, and prescribing for acute lower respiratory tract illness.

Authors:  W F Holmes; J T Macfarlane; R M Macfarlane; R Hubbard
Journal:  Br J Gen Pract       Date:  2001-03       Impact factor: 5.386

Review 7.  New developments in antibacterial choice for lower respiratory tract infections in elderly patients.

Authors:  Anna Maria Ferrara; Anna Maria Fietta
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

8.  A comparative study of the etiology of adult upper and lower respiratory tract infections in the community.

Authors:  David Lieberman; Devora Lieberman; Igor Korsonsky; Miriam Ben-Yaakov; Zilia Lazarovich; Maureen G Friedman; Bella Dvoskin; Maija Leinonen; Bella Ohana; Ida Boldur
Journal:  Diagn Microbiol Infect Dis       Date:  2002-01       Impact factor: 2.803

Review 9.  [Description and role of bacteriological techniques in the management of lung infections].

Authors:  S Dahyot; L Lemee; M Pestel-Caron
Journal:  Rev Mal Respir       Date:  2017-07-05       Impact factor: 0.622

Review 10.  [Managing lower respiratory tract infections in immunocompetent patients. Definitions, epidemiology, and diagnostic features].

Authors:  F Philippart
Journal:  Med Mal Infect       Date:  2006-11-07       Impact factor: 2.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.